Amicus Therapeutics (FOLD) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amicus Therapeutics Announces Full-Year 2014 Financial Results and Corporate Updates
March 3, 2015 4:01 PM ESTMAA Submission for Migalastat Monotherapy for Fabry Disease on Track for Mid-2015 FDA Meeting Scheduled in 1Q15 to Discuss U.S. Pathway
Next-Generation Pompe ERT Set to Enter Clinic in 2H15
CRANBURY, N.J., March 3, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced financial results for the full-year ended December 31, 2014. The Company also provided program updates and reiterated full-year 2015 net cash spend... More
